Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Phase 1 Completed
15 enrolled 21 charts
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Phase 1 Completed
19 enrolled
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
Phase 1 Completed
21 enrolled
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1 Completed
51 enrolled
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1 Completed
185 enrolled 28 charts
BLAST
Phase 1 Completed
22 enrolled
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Phase 1 Completed
36 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1 Completed
56 enrolled 19 charts
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
FORT-2
Phase 1 Completed
37 enrolled 15 charts
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Phase 1 Completed
35 enrolled
ADVANCED-1
Phase 1 Completed
12 enrolled
ADVANCED-1
Phase 1 Completed
10 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
A Study of KF-0210 in Advanced Solid Tumors Patients
Phase 1 Completed
14 enrolled
PrE0807
Phase 1 Completed
43 enrolled 15 charts
MARC
Phase 1 Completed
18 enrolled 11 charts
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
Phase 1 Completed
49 enrolled 12 charts
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Phase 1 Completed
175 enrolled 23 charts
DUET-3
Phase 1 Completed
198 enrolled
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Phase 1 Completed
9 enrolled 13 charts
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Phase 1 Completed
79 enrolled 21 charts
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
Phase 1 Completed
10 enrolled
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Phase 1 Completed
78 enrolled
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
Phase 1 Completed
47 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Phase 1 Completed
71 enrolled
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Phase 1 Completed
23 enrolled
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
Phase 1 Completed
8 enrolled
STORM
Phase 1 Completed
85 enrolled
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Phase 1 Completed
69 enrolled
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Phase 1 Completed
32 enrolled
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Phase 1 Completed
6 enrolled 7 charts
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Phase 1 Completed
12 enrolled
CANON
Phase 1 Completed
16 enrolled 8 charts
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Phase 1 Completed
6 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Phase 1 Completed
53 enrolled
Safety Study of MGA271 in Refractory Cancer
Phase 1 Completed
179 enrolled
First-in-human Study of S-588210 (S-488210+S-488211)
Phase 1 Completed
10 enrolled
A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets
Phase 1 Completed
12 enrolled
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Phase 1 Completed
168 enrolled 59 charts
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Phase 1 Completed
34 enrolled